In other cancer types, notably melanoma and non-small-cell lung cancer, immunotherapeutic approaches, including immune checkpoint inhibitors (such as anti-PD-1 and anti-CTLA-4 antibodies) [33], have demonstrated remarkable success in improving patient outcomes [34, 35]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.